CHF Solutions to Host Webinar Discussing Fluid Management Strategies in Critically Ill COVID-19 Patients
June 12 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced the company will host
an interactive, physician-led webinar to discuss the recent
publication: SARS-CoV-2 (COVID-19) and intravascular volume
management strategies in the critically ill.1 and the role of
ultrafiltration in the treatment of patients with COVID-19.
Registration is open for the webinar, which will feature
perspectives from Italy to the United States and take place on June
17 at 9 a.m. EDT.
COVID-19 has been causing acute respiratory distress syndrome
(ARDS), which can lead to acute kidney injury (AKI). When the
kidneys cannot remove the excess fluid and waste in the body, these
patients can experience kidney failure and multi-organ failure.
Effective fluid management in critically ill COVID patients can
help prevent AKI and mitigate devastating outcomes in these
patients.
Isolated ultrafiltration is an optimal strategy that primarily
focuses on fluid extraction and management of fluid volume.
Portable ultrafiltration devices are proving particularly helpful
in critically ill COVID-19 patients because the extremely small
extracorporeal volume (i.e. 35 ml) helps avoid potentially adverse
hemodynamic impact. The predictability of fluid extraction using
ultrafiltration makes it easier to achieve precise de-escalation.
The ease of use of ultrafiltration therapy and ability to deploy
dedicated ultrafiltration machines quickly has helped hospitals
manage the high number of COVID patients with limited
resources.
Webinar Panelists:
Claudio Ronco, MDNephrologist, International Renal Research
Institute, St Bortolo Hospital, Vicenza, Italy
Peter A. McCullough, MDCardiologist, Baylor University Medical
Center, Dallas, TX
Moderated by:
Ravi Mehta, MDNephrologist, UC San Diego Health-Jacobs Medical
Center, San Diego, CA
The webinar will cover:
- The importance of fluid stewardship in critically ill COVID-19
patients
- Strategies to maintain fluid balance and reduce potential
complications, such as ARDS, AKI and cardiac injury
- Lessons learned while treating COVID-19 patients
“Using evidence-based approaches employed by renowned physicians
working on the front lines in Italy and the United States, this
publication has generated awareness about the importance of fluid
balance when treating critically ill COVID-19 patients,” said John
Erb, CEO of CHF Solutions. “As this pandemic continues, we remain
committed to providing relevant education to the dedicated medical
professionals treating patients suffering with COVID-19. We believe
this webinar will provide further insight into how ultrafiltration
can be a critical tool in the armament for nephrologists treating
COVID-19.”
Register to participate in this webinar:
https://bit.ly/2YrL81A
1. https://pubmed.ncbi.nlm.nih.gov/32336959/
About CHF Solutions CHF Solutions, Inc. (CHFS)
is a medical device company dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the
Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex
SmartFlow system is indicated for temporary (up to 8 hours) or
extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the treatment
of patients infected with the coronavirus. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024